“Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma”
Romano G, Paradiso F, Li P, Shukla P, Barger LN, El Naggar O, Miller JP, Liang RJ, Helms TL, Lazar AJ, Wargo JA, Taraballi F, Costello JCC, Kwong LN
Cancer Immunology Research. 2023

“Tumor Microenvironment and Immune Escape in the Time Course of Glioblastoma”
Virtuoso A, De Luca C, Cirillo G, Riva M, Romano G, Bentivegna A, Lavitrano M, Papa M, Giovannoni R
Molecular Neurobiology. 2022

“Multi-modal molecular programs regulate melanoma cell state and clinical outcomes”
Andrews MC, Oba J, Zhu H, Wu C, Karpinets T, Creasy CA, Forget M, Yu Z, Song X, Mao X, Hoon DSB, Robertson AG, Romano G, Li P, Burton EM, Lu Y, Sloane RS, Wani KM, Rai K, Lazar AJ, Haydu LE, Bustos MA, Shen J, Chen Y, Patel KP, Morgan MB, Wargo JA, Kwong LN, Haymaker CL, Grimm EA, Hwu P, Zhang J, Gershenwald JE, Davies MA, Futreal PA, Bernatchez C, Woodman SE
Nature Communications. 2022

“BTK Inhibitors Synergise with 5-FU to Treat Drug-Resistant TP53-Null Colon Cancers”
Lavitrano, M., Ianzano, L., Bonomo, S., Cialdella, A., Cerrito, M. G., Pisano, F., Missaglia, C., Giovannoni, R., Romano, G., McLean, C. M., Voest, E. E., D'Amato, F., Noli, B., Ferri, G. L., Agostini, M., Pucciarelli, S., Helin, K., Leone, B. E., Canzonieri, V., and Grassilli, E.
J Pathol. 250:134-47.10.1002/path.5347. 2020

“Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype”
Sala, L., Cirillo, G., Riva, G., Romano, G., Giussani, C., Cialdella, A., Todisco, A., Virtuoso, A., Cerrito, M. G., Bentivegna, A., Grassilli, E., Ardizzoia, A., Bonoldi, E., Giovannoni, R., Papa, M., and Lavitrano, M.
Front Mol Neurosci. 12:2.10.3389/fnmol.2019.00002. 2019

“BRAF Dimerization: An Underlying Resistance Mechanism in Low-Grade Pediatric Gliomas”
Romano, G., and Kwong, L. N.
Cancer Discov. 8:1064-65.10.1158/2159-8290.CD-18-0784. 2018

“Diagnostic and Therapeutic Applications of miRNA-Based Strategies to Cancer Immunotherapy”
Romano, G., and Kwong, L. N.
Cancer Metastasis Rev. 37:45-53.10.1007/s10555-017-9716-7. 2018

“APOA-1Milano Muteins, Orally Delivered Via Genetically Modified Rice, Show Anti-Atherogenic and Anti-Inflammatory Properties in Vitro and in Apoe(-/-) Atherosclerotic Mice”
Romano, G., Reggi, S., Kutryb-Zajac, B., Facoetti, A., Chisci, E., Pettinato, M., Giuffre, M. R., Vecchio, F., Leoni, S., De Giorgi, M., Avezza, F., Cadamuro, M., Crippa, L., Leone, B. E., Lavitrano, M., Rivolta, I., Barisani, D., Smolenski, R. T., and Giovannoni, R.
Int J Cardiol. 271:233-39.10.1016/j.ijcard.2018.04.029. 2018

“A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK Plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling”
Romano, G., Chen, P., Song, P., McQuade, J.L., Liang, R.J., Liu, M., Roh, W., Duose, D.Y., Carapeto, F.C. L., Li, J., Teh, J.L.F., Aplin, A.E., Chen,M., Zhang, J., Lazar, A.J., Davies, M.A., Futreal, P.A., Amaria, R.N., Zhang, D.Y., Wargo, J.A., and Kwong, L.N.
Cancer Discovery. 8:556-67.10.1158/2159-8290.Cd-17-0745. 2018

“The Path to Metastatic Mouse Models of Colorectal Cancer”
Romano, G., Chagani, S., and Kwong, L. N.
Oncogene. 37:2481-89.10.1038/s41388-018-0155-x. 2018

“miRNAs, Melanoma and Microenvironment: An Intricate Network”
Romano, G., and Kwong, L. N.
Int J Mol Sci. 18.10.3390/ijms18112354. 2017

“Resveratrol Impairs Glioma Stem Cells Proliferation and Motility by Modulating the Wnt Signaling Pathway”
Cilibrasi, C., Riva, G., Romano, G., Cadamuro, M., Bazzoni, R., Butta, V., Paoletta, L., Dalpra, L., Strazzabosco, M., Lavitrano, M., Giovannoni, R., and Bentivegna, A.
PLoS One. 12:e0169854.10.1371/journal.pone.0169854. 2017

“Thyrospheres from B-CPAP Cell Line with BRAF and TERT Promoter Mutations Have Different Functional and Molecular Features Than Parental Cells”
Caria, P., Pillai, R., Dettori, T., Frau, D. V., Zavattari, P., Riva, G., Romano, G., Pani, F., Bentivegna, A., Giovannoni, R., Pagni, F., Sogos, V., and Vanni, R.
J Cancer. 8:1629-39.10.7150/jca.18855. 2017

“The TGF-β Pathway Is Activated by 5-Fluorouracil Treatment in Drug Resistant Colorectal Carcinoma Cells”
Romano, G., Santi, L., Bianco, M. R., Giuffre, M. R., Pettinato, M., Bugarin, C., Garanzini, C., Savarese, L., Leoni, S., Cerrito, M. G., Leone, B. E., Gaipa, G., Grassilli, E., Papa, M., Lavitrano, M., and Giovannoni, R.
Oncotarget. 7:22077-91.10.18632/oncotarget.7895. 2016

“A Functional Biological Network Centered on XRCC3: A New Possible Marker of Chemoradiotherapy Resistance in Rectal Cancer Patients”
Agostini, M., Zangrando, A., Pastrello, C., D'Angelo, E., Romano, G., Giovannoni, R., Giordan, M., Maretto, I., Bedin, C., Zanon, C., Digito, M., Esposito, G., Mescoli, C., Lavitrano, M., Rizzolio, F., Jurisica, I., Giordano, A., Pucciarelli, S., and Nitti, D.
Cancer Biol Ther. 16:1160-71.10.1080/15384047.2015.1046652. 2015

“Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy”
Grassilli, E., Narloch, R., Federzoni, E., Ianzano, L., Pisano, F., Giovannoni, R., Romano, G., Masiero, L., Leone, B. E., Bonin, S., Donada, M., Stanta, G., Helin, K., and Lavitrano, M.
Clin Cancer Res. 19:3820-31.10.1158/1078-0432.CCR-12-3289. 2013

 
 Back to Top